Cargando…
Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
Tumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by system...
Autor principal: | Glasser, Chana L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678818/ https://www.ncbi.nlm.nih.gov/pubmed/29159035 http://dx.doi.org/10.1016/j.lrr.2017.10.002 |
Ejemplares similares
-
New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
por: Chen, Jing, et al.
Publicado: (2020) -
How mRNA is misspliced in acute myelogenous leukemia (AML)?
por: Mohamed, Aminetou Mint, et al.
Publicado: (2014) -
Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy
por: Rasool, Mahmood, et al.
Publicado: (2014) -
Uric Acid and the Prediction Models of Tumor Lysis Syndrome in AML
por: Ejaz, A. Ahsan, et al.
Publicado: (2015) -
Prognostic Value of AML1/ETO Fusion Transcripts in Patients with Acute Myelogenous Leukemia
por: Cho, Eun Kyung, et al.
Publicado: (2003)